RESUMEN

Medical treatment of fibroma has changed radically in recent years with the introduction of analogs of LH-RH (luteinizing hormone releasing hormone). These agents, which are active only via parenteral administration, have proved remarkably effective, and are devoid of metabolic effects. They do engender some disagreeable adverse reactions, and unfortunately their efficacy is transitory and their cost high. Compared with these analogs, gestrinone, a progestogen as yet unused in treatment of luteal insufficiency, seems very interesting in the treatment of fibromas, due to its prolonged antigonadotropic effect and its antiprogesterone effect. Further studies are required to confirm the first results published by Coutinho.

Asunto(s)

Buserelina/uso terapéutico , Gestrinona/uso terapéutico , Leiomioma/tratamiento farmacológico , Norpregnatrienos/uso terapéutico , Neoplasias Uterinas/tratamiento farmacológico , Administración Intranasal , Adolescente , Adulto , Buserelina/administración & dosificación , Femenino , Gestrinona/administración & dosificación , Humanos , Leiomioma/patología , Persona de Mediana Edad , Inducción de Remisión , Neoplasias Uterinas/patología